scholarly journals Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer

2021 ◽  
Vol 151 ◽  
pp. 221-232
Author(s):  
Robbe Saesen ◽  
Denis Lacombe ◽  
Isabelle Huys
Keyword(s):  
Colorectal Cancer ◽  
European Organisation ◽  
Treatment Optimisation

European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Colorectal Cancer--Dutch Version

2016 ◽  
Author(s):  
A. M. Stiggelbout ◽  
M. Kunneman ◽  
M. C. M. Baas-Thijssen ◽  
P. A. Neijenhuis ◽  
A. K. Loor ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Life Questionnaire ◽  
Dutch Version ◽  
Quality Of Life Questionnaire ◽  
European Organisation

Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer

2008 ◽  
Vol 26 (12) ◽  
pp. 2020-2026 ◽  
Author(s):  
Fabio Efficace ◽  
Pasquale F. Innominato ◽  
Georg Bjarnason ◽  
Corneel Coens ◽  
Yves Humblet ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Social Functioning ◽  
Cancer Patients ◽  
Life Questionnaire ◽  
European Organisation ◽  
Wbc Count ◽  
Colorectal Cancer Patients

Purpose A recent study identified a prognostic model for survival in metastatic colorectal cancer patients which included WBC count, alkaline phosphatase (AP), number of metastatic sites, and patients’ self-reported social functioning. The aim of this research is to validate this model on data from an independent sample. Patients and Methods This validation study is based on a prospective randomized controlled trial in patients with metastatic colorectal cancer conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Chronotherapy Group. Overall, 564 patients in 10 countries were enrolled. For the purpose of this independent validation, patients with health-related quality of life (HRQOL) baseline data were analyzed. HRQOL was assessed using the EORTC Quality of Life Questionnaire C30 (QLQ-C30). The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. Results The previous model with an additional adjustment, by stratification for sex, was replicated and its parameters were confirmed to independently predict survival: WBC count with an hazard ratio (HR) of 1.31 (95% CI, 1.021 to 1.698; P = .034); AP with an HR of 1.53 (95% CI, 1.188 to 1.979; P = .001); number of sites involved with an HR of 1.90 (95% CI, 1.531 to 2.364; P < .0001); and patients’ self-reported social functioning with an HR of 0.94 (95% CI, 0.905 to 0.976; P = .001). The latter translates into a 6% increase in the likelihood of an earlier death for every 10-point decrease in the social functioning scale of the EORTC QLQ-C30. Conclusion This study provides confirmatory evidence of the independent prognostic value of patients’ self-reported social functioning in patients with advanced colorectal cancer.

Deletion mapping on chromosome 6 in colorectal cancer associated with ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A121-A122
Author(s):  
T EZAKI ◽  
M WATANABE ◽  
S FUNAKOSHI ◽  
M NAGANUMA ◽  
T AZUMA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Deletion Mapping ◽  
Chromosome 6

Predicting adherence to colorectal cancer surveillance after plypectomy

2001 ◽  
Vol 120 (5) ◽  
pp. A602-A602
Author(s):  
S RAWL ◽  
S BLACKBURN ◽  
L HACKWARD ◽  
N FINEBERG ◽  
T IMPERIALE ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Surveillance ◽  
Colorectal Cancer Surveillance

Urokinase type plasminogen activator and inhibitor type-1 plasma levels in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A600 ◽  
Author(s):  
L HERSZENYI ◽  
F FARINATI ◽  
G ISTVAN ◽  
M PAOLI ◽  
G ROVERONI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Plasma Levels ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Inhibitor Type

A panel of mono- and dinucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A599
Author(s):  
C ARNOLD ◽  
A GOEL ◽  
J CARETHERS ◽  
L WASSERMAN ◽  
C COMPTON ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Markers ◽  
Reliable Determination

Use of plasma MMP-2 to measure response to surgery and chemoradiotherapy in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A159-A159
Author(s):  
M TUTTON ◽  
M GEORGE ◽  
S ECCLES ◽  
I SWIFT ◽  
M ABULAFI
Keyword(s):  
Colorectal Cancer

Barriers to colorectal cancer (CRS) screening in minority communities: inadequate knowledge of guidelines by physicians in training

2001 ◽  
Vol 120 (5) ◽  
pp. A604-A604
Author(s):  
M GENNARELLI ◽  
L JANDORF ◽  
C CROMWELL ◽  
H VALDIMARSDOTTIR ◽  
W REDD ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Minority Communities ◽  
Inadequate Knowledge
Sign in / Sign up

Export Citation Format

Share Document